Skip to content

May 5, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Clinical Data
QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

Clinical Data

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

BioSpace

Biogen's Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis.

Read full story

pharminent May 5, 2026 (Last updated: May 5, 2026)

BioSpace

Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis.

Read full story

Post navigation

Previous: Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

Related Stories

Clinical Data

Cytokinetics heart drug scores in closely watched trial

pharminent May 5, 2026

Clinical Data

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

pharminent May 4, 2026

Clinical Data

Summit shares descend as PD-1/VEGF asset misses early survival mark

pharminent May 4, 2026

You May Have Missed

Clinical Data

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

pharminent May 5, 2026

Commercial

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

pharminent May 5, 2026

Clinical Data

Cytokinetics heart drug scores in closely watched trial

pharminent May 5, 2026

Market Access

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point

pharminent May 5, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.